US Regulatory Watch — Week of May 20–27, 2026

US Regulatory Watch — Week of May 20–27, 2026

27 regulatory actions from SEC, FDA, and FTC this week. SEC proposes its largest deregulatory shift in 20+ years — expanding shelf registration and cutting ICFR attestation requirements. FTC launches TAKE IT DOWN Act enforcement and settles AI-washing case with Cox Media Group ($930K). FDA approves first-ever HDV treatment and issues CGMP warning letters to three drug manufacturers.

US Regulatory Watch — SEC / FDA / FTC
US Regulatory Watch — SEC / FDA / FTC@NeoDrop Official
2026. 5. 27. · 21:59
구독 1개 · 콘텐츠 1개
The most consequential regulatory output this week came from the SEC, which published two paired proposed rules that would collectively expand access to registered capital markets for an estimated 60% more issuers while eliminating the ICFR auditor attestation requirement for roughly 81% of all public companies. The proposals represent the broadest proposed overhaul of the securities issuance framework in more than 20 years. At the enforcement layer, all three agencies moved aggressively: the SEC charged an insider trader who acted on spousal MNPI in the Adobe–Semrush deal; the FTC settled its 13th AI-washing case and formally launched enforcement of the TAKE IT DOWN Act (TIDA); and the FDA approved the first-ever treatment for chronic hepatitis delta while issuing CGMP warning letters to foreign-owned drug manufacturers.

SEC: major rulemaking proposals and enforcement actions

Registered Offering Reform — the flagship deregulatory proposal

On May 26, the SEC published in the Federal Register its Registered Offering Reform proposed rule (S7-2026-17, Release Nos. 33-11418 / 34-105513 / IC-36160, 91 FR 31022), 1 2 a 260-page document that would restructure the mechanics of how public companies access registered equity and debt markets.
The core changes are sweeping:
  • Form S-3 eligibility would be extended to nearly all Exchange Act reporting companies that have been current in their filings for at least one year — a change the SEC estimates would increase the number of qualified issuers by approximately 60%.
  • Enhanced registration conveniences currently available only to Well-Known Seasoned Issuers (WKSIs) — including automatic shelf effectiveness and expanded communications latitude — would be extended to all exchange-listed companies, widening the benefit by an additional 200%.
  • All Form S-1 filers would be permitted to incorporate by reference, streamlining preparation costs.
  • State Blue Sky registration and qualification requirements for all registered offerings would be federally preempted.
  • The public float requirement and other market-following metrics as conditions for Form S-3 access would be eliminated.
Companion amendments touch BDCs, closed-end funds (Form N-2), and non-variable annuity product advertising.
SEC Chairman Paul S. Atkins described the proposal as foundational to his agenda, stating at the Stanford Rock Center for Corporate Governance on May 26: "Today, the Commission proposed two rulemakings that serve as the foundation for my agenda to Make IPOs Great Again." 3 The comment period closes July 27, 2026 (docket S7-2026-17).
The size of this proposal — if finalized — would give smaller and mid-market public companies shelf-registration and communications flexibility previously only available to the largest issuers. Companies currently unable to use Form S-3 for primary offerings should assess whether they would qualify under the new thresholds.

Filer Status Simplification — 81% of public companies would lose the ICFR attestation requirement

Published on May 21 (S7-2026-18, Release Nos. 33-11419 / 34-105515, 91 FR 30086), 4 5 the companion rulemaking would compress the current three-tier filer classification (Large Accelerated Filer / Accelerated Filer / Non-Accelerated Filer) into two: Large Accelerated Filers (LAF) and Non-Accelerated Filers (NAF).
Key thresholds and consequences:
  • The LAF public float threshold rises from $700 million to $2 billion. Newly public companies would be ineligible for LAF classification for at least 60 months.
  • All companies classified as NAF — including the currently separate Accelerated Filer tier — would be exempt from the ICFR auditor attestation requirement under Sarbanes-Oxley Section 404(b). The SEC estimates this affects approximately 81% of public companies.
  • The smallest NAF companies (bottom 18% by total assets) would receive an additional 30 days to file their annual 10-K and five additional days for quarterly 10-Q filings.
The comment period closes July 20, 2026 (docket S7-2026-18).
For Accelerated Filers currently subject to 404(b) attestation, this proposal warrants attention. If finalized, auditor attestation costs for affected companies could fall significantly — but the corresponding reduction in external verification is also a consideration for audit committee planning.

Enforcement: insider trading, whistleblower violation, and a final judgment

Foot Locker, Inc. (NYSE: FL) settled an administrative proceeding on May 22 after the SEC found that approximately 148 separation agreements signed between July 2020 and June 2024 contained provisions requiring departing employees to waive any right to receive whistleblower awards — a direct violation of Exchange Act Rule 21F-17(a). 6 The affected employees included senior executives and staff across finance, legal, supply chain, and operations. Foot Locker phased out the language between March and June 2024. The settlement: a cease-and-desist order and a $148,000 civil penalty. Foot Locker neither admitted nor denied the findings.
Nipun Kumar Jami (San Jose, CA) settled on May 22 for $1,975,850 (disgorgement of $1,317,233 plus a $658,617 civil penalty) after the SEC found he traded Semrush Holdings call options between November 8 and 18, 2025, based on material nonpublic information he obtained from his spouse — an Adobe employee involved in the then-pending acquisition of Semrush. 7 Semrush stock rose 74% on November 19 when the deal was announced pre-market. Notably, Jami voluntarily reported himself to SEC staff approximately one month after the trades, which the SEC credited in structuring the resolution. Violations cited: Exchange Act Section 10(b) and Rule 10b-5.
A federal court in Alabama entered a final consent judgment on May 20 against James Blake Daughtry, a former Alabama investment adviser, imposing a permanent bar from the securities industry and a $50,000 civil penalty. 8 The underlying allegation — originating from a 2022 complaint — was that Daughtry referred clients to GraySail Advisors without fulfilling his monitoring obligations, while co-defendant Jared D. Eakes subsequently misappropriated approximately $2.6 million from those clients. The case against Eakes continues in the Middle District of Florida.

SEC rescinds 50-year no-deny settlement policy

Effective May 18, the SEC rescinded Rule 202.5(e), 9 which had required defendants settling enforcement actions to refrain from publicly denying the SEC's allegations — a requirement that had been in place for more than 50 years. Chairman Atkins stated: "For more than 50 years, the Commission has conditioned settlement on a defendant's promise not to publicly deny the Commission's allegations. I am pleased that we are rescinding the no-deny policy today." 9 Commissioner Hester M. Peirce commented: "Settlements shrouded in forced silence by the non-governmental party do not serve either the markets or the Commission's investor-protection mission." 10
The SEC will not retroactively enforce no-deny clauses in existing settlements and does not plan to seek rescission of prior orders if defendants speak publicly. The practical near-term impact is limited — no documented case of the SEC ever pursuing a defendant for violating a no-deny clause exists — but defendants in current and future negotiations now have explicit contractual latitude to publicly contest the SEC's narrative post-settlement.
Chairman Atkins also issued a statement on May 20 noting that several novel ETF sponsors had voluntarily delayed fund launches, including event-contract ETFs, while the SEC assesses next steps. 11 A public comment solicitation on IPO modernization (File Number CLL-16) — covering potential changes to gun-jumping rules under Securities Act Section 5 and barriers to direct listings — also opened this week with a comment deadline of July 27, 2026. 12
통계 카드를 불러오는 중…

FDA: landmark approval, large-scale device correction, and CGMP enforcement

First HDV treatment approved — Gilead's Hepcludex

On May 22, the FDA approved Hepcludex (bulevirtide-gmod) injection, the first treatment for chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis. 13 HDV requires co-infection with hepatitis B and affects an estimated 5% of the global HBV population; no FDA-approved treatment had previously existed. The approval was granted under Accelerated Approval with Breakthrough Therapy and Orphan-Drug designations.
Sponsor: Gilead Sciences, Inc.
Phase 3 MYR301 trial results: 48% combined virologic response at Week 48 for patients receiving Hepcludex versus 2% in the delayed treatment control arm; undetectable HDV RNA rose from 20% at Week 48 to 50% at Week 144.
The label carries a boxed warning: discontinuation may cause severe acute exacerbations of both HDV and HBV infection. Wendy Carter, D.O., Acting Director of the Office of Infectious Diseases at FDA's Center for Drug Evaluation and Research (CDER), stated: "Today's approval fills a critical gap in care for patients with chronic HDV infection, who until now have had no FDA-approved therapies available." 13 As an accelerated approval, Hepcludex will require post-market confirmatory studies.

Insulet Omnipod — voluntary correction for ~7 million pods

On May 26, Insulet Corporation (NASDAQ: PODD) announced a voluntary Medical Device Correction for specific lots of Omnipod 5, Omnipod DASH, and Omnipod Eros Pods due to a manufacturing defect causing a small tear in the cannula just above the skin, creating a risk of insulin under-delivery. 14 Approximately 7 million pods are affected, representing roughly 8.5% of 2025 global Omnipod Pod production; Insulet estimates about 60% were already consumed or expired at the time of the announcement. Globally, 24 serious adverse events including hospitalizations and diabetic ketoacidosis (DKA) have been reported — no deaths. Insulet identified the root cause and states replacement supply is available. Users can check their lot numbers at omnipod.com/mdc/check-pod-lot. This correction is separate from a March 12, 2026 Omnipod 5 correction in the US.
Two Class I device recalls were also posted this week: the Omnicell i.v.STATION automated compounding system sterile syringe label recall was upgraded from Early Alert to Class I on May 21, 15 citing inconsistent label detection that could produce unlabeled syringes. On May 22, FDA posted a Class I recall for Bolton Medical's (Terumo Aortic) RelayPro Thoracic StentGraft System (Recall #Z-2160-2026), citing a labeling update related to potential proximal clasp disconnection that could prevent stent graft release from the delivery system. 16 Affected sizes span 28mm through 46mm proximal diameters; distribution included the US, Puerto Rico, and several Latin American and European markets.

CGMP warning letters: three drug manufacturers

FDA issued warning letters this week to three drug manufacturers over serious Good Manufacturing Practice (CGMP) deficiencies:
Alchymars ICM SM Private Limited (Tamil Nadu, India), an active pharmaceutical ingredient (API) manufacturer for the US market, received Warning Letter #320-26-77 on May 21. 17 The November–December 2025 inspection found cracked and taped gaskets, rust-like residues on product-contact surfaces, water condensation dripping onto production equipment, and cleaning records that documented equipment condition as satisfactory when it was visibly deteriorated. Import Alert 66-40 was placed on all drugs from this facility on May 19.
Sato Pharmaceutical Co., Ltd. (Tokyo, Japan) received Warning Letter #320-26-75, posted May 26 with a May 18 issue date. 18 The November 2025 inspection documented at least six media fill failures in the sterile production line between November 2022 and February 2025, unidirectional airflow failures during RABS interventions, and the absence of testing for Burkholderia cepacia complex in water-based products. US-market production is halted pending discussion of corrective actions with the FDA.
GC America, Inc. (Alsip, Illinois) received Warning Letter #320-26-76, posted May 26 with a May 14 issue date. 19 Violations included failure to test incoming components for identity or diethylene glycol (DEG)/ethylene glycol (EG) contamination, no functioning stability program (only one batch tested at 25°C, no humidity control, no ongoing studies), and systemic data-integrity failures including a shared password on a sticker, data auto-deleted on laptop shutdown, and no annual product reviews since 2018. The last FDA inspection was in 2018.

Tobacco enforcement and unapproved drug products

FDA's Center for Tobacco Products (CTP) issued warning letters on May 20 to eight retailers selling unauthorized tobacco products designed to resemble candy, breath strips, or cough drops. 20 Bret Koplow, Ph.D., J.D., Acting Director of FDA CTP, stated: "No tobacco product should look like candy — it's a blatant ploy to target children and mask the true nature of these products." 20 FDA has now issued over 800 warning letters to manufacturers and over 1,000 to retailers for unauthorized tobacco products.
Side-by-side comparison of tobacco products with candy-like packaging, cited in FDA's May 20 enforcement action 20
Separately, FDA issued parallel warning letters on May 18 to GSC Products, LLC (Duanesburg, NY) for SINUS PLUMBER Headache Nasal Spray and Aja Health and Wellness Inc. (Vancouver, Canada) for Aja Migraine Relief nasal spray — both unapproved OTC migraine products with active ingredients not permitted under the OTC nasal analgesics monograph (M013). 21 22 Both letters were signed by the same CDER official, indicating a coordinated enforcement sweep against unapproved OTC nasal migraine products.

FTC: TIDA enforcement launch, AI-washing, and payment fraud

TAKE IT DOWN Act enforcement begins

On May 19, the FTC formally began enforcing TIDA (the TAKE IT DOWN Act), 23 the law signed in May 2025 that requires platforms to provide a mechanism for victims to request removal of nonconsensual intimate images, with a mandatory 48-hour removal window. Civil penalties reach up to $53,088 per violation.
The following day, May 20, the FTC sent warning letters to 12 companies operating "nudify" tools — applications that generate nonconsensual sexualized imagery by digitally removing clothing from images. 24 The FTC did not name the 12 recipients. The prior week, Chairman Andrew N. Ferguson had already sent TIDA compliance reminders to 15 major platforms including Alphabet, Amazon, Apple, Meta, Microsoft, TikTok, and X.
Ferguson stated: "Today we're demonstrating just how serious we are about protecting the public, especially children, from abusive online conduct." 24 He added: "Platforms no longer have any excuses — they must comply with their obligations under the TAKE IT DOWN Act or face the consequences." 24 The sequencing — TIDA effective date, major-platform reminders, then enforcement letters to nudify-specific operators — suggests a deliberate enforcement ramp-up rather than a single action.

Cox Media Group — $930K AI-washing settlement

On May 21, the FTC filed administrative complaints and proposed consent orders against Cox Media Group (CMG), MindSift LLC, and 1010 Digital Works LLC for falsely marketing an "Active Listening" AI service that claimed to target advertisements based on detecting speech from consumers' smart devices. 25 Total settlement: $930,000 (CMG $880,000; MindSift $25,000; 1010 Digital Works $25,000).
The service did not use voice data. The companies were instead reselling email lists purchased from data brokers at a markup. They also falsely claimed that consumers had opted in via app terms of service. Christopher Mufarrige, Director of the FTC Bureau of Consumer Protection, stated: "Not only did the product these companies marketed not do what they claimed it did, but they also misled potential customers by claiming consumers had opted into this service when it's clear they did not." 25
This is the FTC's 13th AI-washing case since 2024 and seven of the last eight involved business-to-business marketing claims. MindSift and 1010 Digital Works face a second count under the "means and instrumentalities" doctrine for supplying CMG with deceptive marketing tools — only the second M&I charge in an AI-related matter after the December 2025 Rytr order. The 30-day public comment period begins upon Federal Register publication.

Additional enforcement actions

Shutterstock Inc. (NYSE: SSTK) agreed on May 13 to pay $35 million to settle FTC allegations over deceptive subscription and cancellation practices. 26 The FTC alleged that Shutterstock's on-demand image packs — marketed as "Best for a one-time project" with "no commitment" — auto-renewed when the last download was used, that material terms were not clearly disclosed, and that consumers could not cancel online until early 2024. Filed in the Southern District of New York, 2-0 vote.
A federal court in Nevada held Cliq Inc. (formerly Cardflex Inc.) and executives Andrew Phillips and John Blaugrund in civil contempt of a 2015 FTC order on May 13, imposing $6.5 million in sanctions. 27 Cliq had processed hundreds of millions of dollars for merchants on Mastercard's MATCH (high-risk merchant) list, helped merchants avoid fraud-monitoring triggers by structuring transactions, and accepted applications with fraudulent websites — all in violation of the 2015 order. The FTC announced the contempt ruling on May 19.
In the ongoing PBM insulin-pricing case, the FTC on May 22 granted a joint motion to stay the administrative proceeding against Caremark Rx (CVS Health, NYSE: CVS), Zinc Health Services, and Optum respondents, rescheduling the evidentiary hearing and extending the Commission's ruling deadline. The case continues. 28
통계 카드를 불러오는 중…

Forward-looking signals

Compliance and legal teams should track the following near-term deadlines and events arising from this week's actions:
DateAgencyItem
May 28FDA VRBPACAdvisory committee meeting to recommend 2026–2027 COVID-19 vaccine formula (docket FDA-2026-N-3962)
July 20SECComment deadline — Filer Status Simplification (S7-2026-18)
July 27SECComment deadline — Registered Offering Reform (S7-2026-17)
July 27SECComment deadline — IPO Modernization public comment solicitation (File No. CLL-16)
TBDFTCCaremark Rx / CVS Health / Optum — rescheduled evidentiary hearing date
TBDFTCCox Media Group AI-washing consent orders — final after 30-day Federal Register comment period
The paired SEC proposed rules share a comment deadline cluster in late July. Organizations that stand to benefit from — or be structurally affected by — shelf registration expansion or the ICFR exemption change should engage with the rulemaking record before the comment windows close. The IPO modernization solicitation (CLL-16) covers a separate but related reform track targeting gun-jumping rules and direct listing barriers; comments here also close July 27.
For FDA manufacturing compliance, the Alchymars Import Alert 66-40, the Sato sterile production halt, and the GC America data-integrity findings reflect consistent FDA CGMP scrutiny of foreign and domestic OTC drug manufacturers. Companies relying on any of these three facilities for US-market supply should assess alternative sourcing. More broadly, foreign API suppliers and OTC drug manufacturers should treat this cluster of letters as a signal that FDA CGMP inspection intensity remains elevated.
Cover image: AI-generated editorial illustration

참고 출처

  1. 1SEC Registered Offering Reform — proposed rule
  2. 2Federal Register 91 FR 31022
  3. 3SEC Press Release 2026-46
  4. 4SEC Filer Status Simplification — proposed rule
  5. 5Federal Register 91 FR 30086
  6. 6SEC Administrative Proceeding 34-105542-S (Foot Locker)
  7. 7SEC Administrative Proceeding 34-105550-S (Jami insider trading)
  8. 8SEC Litigation Release LR-26557 (Daughtry)
  9. 9SEC Press Release 2026-45 — no-deny policy rescission
  10. 10Commissioner Peirce statement on settlement policy
  11. 11SEC Statement on Novel ETFs (May 20)
  12. 12SEC Remarks at Stanford Rock Center (May 26)
  13. 13FDA press announcement — Hepcludex approval
  14. 14FDA recall notice — Insulet Omnipod correction
  15. 15FDA CDRH recall — Omnicell i.v.STATION
  16. 16FDA CDRH recall — RelayPro Thoracic StentGraft
  17. 17FDA CDER Warning Letter — Alchymars ICM SM
  18. 18FDA CDER Warning Letter — Sato Pharmaceutical
  19. 19FDA CDER Warning Letter — GC America
  20. 20FDA CTP press announcement — tobacco retailer warning letters
  21. 21FDA CDER Warning Letter — GSC Products
  22. 22FDA CDER Warning Letter — Aja Health and Wellness
  23. 23FTC press release — FTC begins enforcing TIDA
  24. 24FTC press release — TIDA warning letters to nudify companies
  25. 25FTC press release — Cox Media Group AI-washing settlement
  26. 26FTC press release — Shutterstock settlement
  27. 27FTC press release — Cliq contempt
  28. 28FTC Caremark Rx stay order — May 22, 2026
US Regulatory Watch — SEC / FDA / FTC
US Regulatory Watch — SEC / FDA / FTC

이 콘텐츠를 둘러싼 관점이나 맥락을 계속 보강해 보세요.

  • 로그인하면 댓글을 작성할 수 있습니다.